Results 1 to 10 of about 1,994,731 (278)

RANK and RANK ligand expression in primary human osteosarcoma. [PDF]

J Bone Oncol, 2015
Receptor activator of nuclear factor kappa-B ligand (RANKL) is an essential mediator of osteoclast formation, function and survival. In patients with solid tumor metastasis to the bone, targeting the bone microenvironment by inhibition of RANKL using denosumab, a fully human monoclonal antibody (mAb) specific to RANKL, has been demonstrated to prevent ...
Branstetter D, Rohrbach K, Huang LY, Soriano R, Tometsko M, Blake M, Jacob AP, Dougall WC.   +7 more
europepmc   +5 more sources

Correlating RANK ligand/RANK binding kinetics with osteoclast formation and function. [PDF]

J Cell Biochem, 2015
ABSTRACTThe interaction between Receptor Activator of NF‐κB Ligand (RANKL) and its receptor RANK is essential for the differentiation and bone resorbing capacity of the osteoclast. Osteoprotegerin (OPG), a soluble homodimer, acts as a decoy receptor for RANKL and thus inhibits osteoclastogenesis.
Warren JT, Zou W, Decker CE, Rohatgi N, Nelson CA, Fremont DH, Teitelbaum SL.   +6 more
europepmc   +5 more sources

The role of RANK ligand/osteoprotegerin in rheumatoid arthritis. [PDF]

Ther Adv Musculoskelet Dis, 2012
In the complex system of bone remodeling, the receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) pathway is the coupling factor between bone formation and bone resorption. RANKL binds to the RANK receptor of pre-osteoclasts and mature osteoclasts and stimulates their activation and differentiation. The production of RANKL/OPG
Geusens P.
europepmc   +5 more sources

DeepBindPoc: a deep learning method to rank ligand binding pockets using molecular vector representation. [PDF]

PeerJ, 2020
Accurate identification of ligand-binding pockets in a protein is important for structure-based drug design. In recent years, several deep learning models were developed to learn important physical–chemical and spatial information to predict ligand ...
Zhang H, Saravanan KM, Lin J, Liao L, Ng JT, Zhou J, Wei Y.   +6 more
europepmc   +2 more sources

Circulating Receptor Activator of Nuclear Factor-κB (RANK), RANK ligand (RANKL), and Mammographic Density in Premenopausal Women. [PDF]

Cancer Prev Res (Phila), 2018
The receptor activator of nuclear factor-κB (RANK) pathway plays essential roles in breast development. Mammographic density is a strong risk factor for breast cancer, especially in premenopausal women.
Toriola AT, Appleton CM, Zong X, Luo J, Weilbaecher K, Tamimi RM, Colditz GA.   +6 more
europepmc   +2 more sources

RANK-ligand and osteoprotegerin as biomarkers in the differentiation between periprosthetic joint infection and aseptic prosthesis loosening. [PDF]

World J Orthop, 2017
AIM To assess serum levels of RANK-ligand (RANKL) and osteoprotegerin (OPG) as biomarkers for periprosthetic joint infection (PJI) and compare their accuracy with standard tests.
Friedrich MJ, Wimmer MD, Schmolders J, Strauss AC, Ploeger MM, Kohlhof H, Wirtz DC, Gravius S, Randau TM.   +8 more
europepmc   +2 more sources

RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. [PDF]

Breast Cancer Res, 2015
IntroductionRANKL is important in mammary gland development during pregnancy and mediates the initiation and progression of progesterone-induced breast cancer.
Azim HA, Peccatori FA, Brohée S, Branstetter D, Loi S, Viale G, Piccart M, Dougall WC, Pruneri G, Sotiriou C.   +9 more
europepmc   +2 more sources

Implicating Receptor Activator of NF-κB (RANK)/RANK Ligand Signalling in Microglial Responses to Toll-Like Receptor Stimuli.

Dev Neurosci, 2017
Inflammation in the perinatal brain caused by maternal or intrauterine fetal infection is now well established as an important contributor to the development of perinatal brain injury.
Kichev A, Eede P, Gressens P, Thornton C, Hagberg H.   +4 more
europepmc   +2 more sources

Rank ligand as a target in musculoskeletal neoplasms. [PDF]

Curr Rev Musculoskelet Med, 2015
Receptor activator of nuclear factor-κB ligand (RANKL) is a tumor necrosis factor (TNF) family member, which signals through the osteoclast surface RANK. As such, RANKL is required for osteoclast differentiation and function, namely bone resorption. There is now growing evidence that RANKL is a therapeutic target for musculoskeletal neoplasms, namely ...
Cote GM.
europepmc   +4 more sources

RANK-Ligand inhibitor associated osteonecrosis of the jaw. [PDF]

GMS Interdiscip Plast Reconstr Surg DGPW, 2013
Osteonecrosis of the jaw may be caused by many different triggers. One of them is described to be the drug or medication related osteonecrosis of the jaw. Since many years bisphosphonates induced the dreaded diagnosis. Recently a drug named denosumab is reported to show similar effects on the jaw.
Rashad A, Smeets R, Heiland M.
europepmc   +5 more sources